Bronchogen
Bronchogen is a bioregulatory tetrapeptide (Ala-Glu-Asp-Leu) with tissue-specific effects in the lungs, studied for its ability to stabilize DNA, reduce inflammation, and promote epithelial repair in pulmonary tissue. Research indicates geroprotective properties through regulation of DNA transcription pathways and reduction of age-related lung function decline.
Bronchogen is a synthetic bioregulatory tetrapeptide with tissue-specific effects in the lungs. Research in rat models demonstrates that Bronchogen can decrease inflammation and reestablish healthy lung tissue states by affecting several DNA transcription pathways, resulting in improved epithelium, increased surfactant production, and reduced inflammation.
Overview
Bronchogen (Ala-Glu-Asp-Leu) is a DNA-stabilizing peptide just four amino acids in length (Monaselidze et al., 2011). Research shows that it acts as a bioregulator, particularly in lung tissue, stimulating the growth, proliferation, and differentiation of certain cell lines (Khavinson et al., 2012). Bronchogen appears to increase the levels of certain DNA transcription factors and reverse age-related declines in DNA transcription. The peptide has been investigated for its ability to treat lung conditions, as a possible plant growth factor, and as an anti-aging geroprotective agent.
Mechanism of Action
DNA Stabilization
Microcalorimeter measurements indicate that DNA in the presence of Bronchogen has a higher melting point than DNA otherwise, suggesting enhanced structural stability (Monaselidze et al., 2011). Greater DNA stability correlates with less degradation over time and reduced telomerase activation. While telomerase protects telomeres and prevents cellular senescence from overly short chromosomes, excessive telomerase activity is also associated with increased cancer risk — damaged DNA that triggers telomerase can prevent normal apoptotic mechanisms from clearing cells with aberrant DNA.
By stabilizing DNA, Bronchogen reduces damage accumulation over time and decreases cell turnover rates. This lessens the need for telomerase activity while allowing DNA to remain healthy for longer, preventing the transition of cells into senescence or apoptosis. The net result is improved overall tissue health because cells remain functional for longer periods and preserve the limited regenerative capacity of stem cell populations.
Growth Factor Activity
Research in rat models shows that Bronchogen and similar peptides have a stimulating effect, even at very low concentrations, on cellular repair processes (Khavinson et al., 2012). This effect appears to be mediated through increases in CXCL12 and Hoxa factors, both transcription factors that regulate cascades affecting growth and differentiation. The effects of these transcription factors are more prominent in older cell lines than younger ones — the older cells are, the more they benefit from Bronchogen administration, with increases in growth and differentiation leading to improved tissue health.
These effects are tissue-specific: Bronchogen exerts its primary effects on lung tissue and has relatively few off-target effects in other tissues, suggesting that mechanisms exist to control the specificity of short, membrane-penetrating peptides within cells.
Reconstitution Calculator
Reconstitution Calculator
Calculate your peptide dosing
Set up a clean workspace with all supplies ready.
7x / week for weeks
Research
Plant Growth Regulation
Bronchogen, along with Epithalon, increases growth and regeneration in plant tissue by activating several regulatory pathways including the CLE pathway, KNOX1 transcription factors, and GRFs (growth regulatory factors) that bind to DNA and regulate transcription (Fedoreyeva et al., 2017). This work underscores the function of Bronchogen as a DNA regulatory factor controlling growth, proliferation, and differentiation across biological kingdoms.
Pulmonary Disease
Bronchogen is highly effective against certain pulmonary conditions in rat models, including chronic obstructive pulmonary disease (COPD) and asthma. The peptide helps prevent and alleviate the remodeling that occurs in these diseases, ameliorating the aberrant immune response that causes hyperplasia, dysplasia, and the death of ciliated cells. It also reduces levels of pro-inflammatory cytokines, decreasing inflammation and helping to prevent scarring and fibrosis (Kuzubova et al., 2015).
Research in rats demonstrates that Bronchogen can restore the epithelium of the lungs following induction of COPD and other inflammatory diseases, resulting in increased surfactant production and reduced alveolar surface tension. This means Bronchogen targets the causative process of disease progression rather than simply treating symptoms — boosting surfactant production increases the ability of the lungs to exchange oxygen and carbon dioxide, while restoring ciliated epithelial cells helps efficiently distribute surfactant and remove debris.
Safety Profile
Bronchogen has demonstrated a favorable safety profile in preclinical studies, with no significant adverse effects reported in rat models at standard research doses. As a short tetrapeptide composed of naturally occurring amino acids, it is rapidly metabolized and does not accumulate in tissues. Its tissue-specific activity in the lungs suggests limited off-target effects. However, human clinical safety data remains limited, and long-term effects have not been fully characterized.
Pharmacokinetic Profile
- Half-life
- Minutes (short peptide); effects persist via epigenetic changes
Quick Start
- Typical Dose
- 10-20 mg oral or 10 mg injectable
- Frequency
- Daily for 10-20 days per cycle
- Route
- Oral, Subcutaneous
- Cycle Length
- 10-20 days
- Storage
- Oral capsules: room temperature. Injectable: 2-8°C refrigerated
Molecular Structure
- Weight
- 432 Da
- Length
- 4 amino acids
- CAS
- Not available
Research Indications
Respiratory Support
Supports bronchial tissue through gene expression regulation.
Helps maintain respiratory epithelium health.
Regulates protein synthesis in lung tissue.
Anti-Aging
Addresses age-related changes in bronchial tissue.
Modulates gene expression in respiratory cells.
Research Protocols
oral
Available in capsule form for oral administration. Short peptides can be absorbed orally and reach target tissues. Typical protocol involves 10-20 day cycles.
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| Standard protocol | 10-20 mg | Daily for 10-20 days | —(Route: Oral capsules) |
subcutaneous Injection
Injectable form available for direct administration.
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| Research protocol | 10 mg | Daily for 10 days | —(Route: IM or SubQ) |
Reconstitution Guide (mg vial + mL BAC water)
- Clean work area thoroughly
- Reconstitute with appropriate volume
- Gently swirl until dissolved
- Store reconstituted solution refrigerated
Interactions
Peptide Interactions
Related respiratory bioregulators; complementary mechanisms.
Often combined in comprehensive anti-aging Khavinson protocols.
Both have immune-modulating properties; different tissue targets.
Part of Khavinson bioregulator family; targets different tissue.
What to Expect
What to Expect
Gene expression modulation begins
Effects persist due to epigenetic changes
Respiratory function improvements
Cumulative benefits with periodic cycles
Safety Profile
Common Side Effects
- Generally well-tolerated
- Minimal side effects reported
Contraindications
- Active respiratory emergencies (seek medical care)
- Known hypersensitivity
- Pregnancy or breastfeeding
Discontinue If
- Allergic reactions
- Unusual respiratory symptoms
Quality Indicators
What to look for
- White powder or capsules
- Clear solution if reconstituted
- Proper packaging and labeling
Caution
- Unknown source or purity
Red flags
- Discoloration
- Unusual odor
- Damaged packaging
Frequently Asked Questions
References (8)
- [1]Khavinson Peptide Bioregulators (2020)
- [2]Short Peptides and Bronchial Function (2018)
- [3]Bioregulator Peptides and Respiratory Health (2016)
- [1][Monaselidze JR et al. (2011). Effect of the peptide bronchogen (Ala-Asp-Glu-Leu) on DNA thermostability. Bull Exp Biol Med (2011)
- [2][Khavinson VK et al. (2012). Peptides tissue-specifically stimulate cell differentiation during their aging. Bull Exp Biol Med (2012)
- [4][Fedoreyeva LI et al. (2017). Short Exogenous Peptides Regulate Expression of CLE, KNOX1, and GRF Family Genes in Nicotiana tabacum. Biochemistry (Mosc) (2017)
- [3][Kuzubova NA et al. (2015). Modulating Effect of Peptide Therapy on the Morphofunctional State of Bronchial Epithelium in Rats with Obstructive Lung Pathology. Bull Exp Biol Med (2015)
- [5][Khavinson VK et al. (2021). Peptide Regulation of Gene Expression: A Systematic Review. Molecules (2021)
Bradykinin
Bradykinin is a vasoactive nonapeptide generated from high-molecular-weight kininogen by the serine protease kallikrein. Acting through constitutive B2 and inducible B1 receptors, it is a potent mediator of vasodilation, vascular permeability, pain, and inflammation, with major clinical relevance in ACE inhibitor side effects, hereditary angioedema, and inflammatory disease.
Buserelin
Buserelin is a synthetic GnRH agonist with a D-Ser(tBu)6 substitution and C-terminal ethylamide modification, approximately 40x more potent than native GnRH. Marketed as Suprefact and Suprecur, it is used clinically for prostate cancer, endometriosis, and IVF downregulation, with wider adoption in Europe, Canada, and Australia than the United States.